Click here to view the PubMed list of Dr. Abrams publications.

Stewart TJ, Liewehr DJ, Steinberg SM, Greeneltch KM, Abrams SI.  Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells.  J Immunol. 2009 Jul 1;183(1):117-28.

Stewart TJ, Greeneltch KM, Reid JE, Liewehr DJ, Steinberg SM, Liu K, Abrams SI.  Interferon regulatory factor-8 modulates the development of tumor-induced CD11bGr-1 myeloid cells.  J Cell Mol Med. 2009 Jan 28. [Epub ahead of print]

Stewart TJ, Abrams SI.  How tumours escape mass destruction.  Oncogene. 2008 Oct 6;27(45):5894-903. Review

Stewart TJ, Lutsiak ME, Abrams SI.  Immune consequences of protracted host-tumor interactions in a transgenic mouse model of mammary carcinoma.  Cancer Invest. 2008 Apr-May;26(3):237-49.

Greeneltch KM, Schneider M, Steinberg SM, Liewehr DJ, Stewart TJ, Liu K, Abrams SI. Host immunosurveillance controls tumor growth via IFN regulatory factor-8 dependent mechanisms. Cancer Res. 2007 Nov 1;67(21):10406-16.

Yang D, Stewart TJ, Smith KK, Georgi D, Abrams SI, Liu K. Downregulation of IFN-gammaR in association with loss of Fas function is linked to tumor progression. Int J Cancer. 2008 Jan 15;122(2):350-62.

Yang D, Ud Din N, Browning DD, Abrams SI, Liu K. Targeting lymphotoxin beta receptor with tumor-specific T lymphocytes for tumor regression. Clin Cancer Res. 2007 Sep 1;13(17):5202-10.

Stewart TJ, Abrams SI. Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J Immunol. 2007 Sep 1;179(5):2851-9.

Yang D, Thangaraju M, Greeneltch K, Browning DD, Schoenlein PV, Tamura T, Ozato K, Ganapathy V, Abrams SI, Liu K. Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res. 2007 Apr 1;67(7):3301-9.

Stewart TJ, Greeneltch KM, Lutsiak ME, Abrams SI. Immunological responses can have both pro- and antitumour effects: implications for immunotherapy. Expert Rev Mol Med. 2007 Feb 7;9(4):1-20. Review.